JPMorgan analyst Jessica Fye lowered the firm’s price target on United Therapeutics (UTHR) to $330 from $350 and keeps an Overweight rating on the shares. The firm sees the upcoming Phase III TETON 2 data for Tyvaso in idiopathic pulmonary fibrosis as a key event for the stock. The readout offers “significantly more upside than downside,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
- United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis
- United Therapeutics price target lowered to $385 from $410 at UBS
- Liquidia price target lowered to $40 from $45 at BTIG
- United Therapeutics Shareholders Approve Key Resolutions